Welcome to Helix Talk, an educational podcast for healthcare students and providers covering real-life clinical pearls, professional pharmacy topics, and drug therapy discussions.

This podcast is provided by pharmacists and faculty members at Rosal Franklin University College of Pharmacy.

This podcast contains general information for educational purposes only. This is not professional

advice and should not be used in lieu of obtaining advice from a qualified health care provider.

And now on to the show. Welcome to Helix Talk episode 103. I'm your co-host Dr. Kane.

And I'm Dr. Patal. And the title of today's episode is, how can peeing sugar improve heart failure?

No one knows, but we know it works.

Yes, and we're going to talk all about it today.

Pea sugar.

And really what we're talking about is a new trial that was published in the New England Journal of Medicine.

This was September 19th, called the DAPA

HF trial. And it was looking at the Paglphosin brand name Farsiga, which is typically a diabetes

drug. And it was actually studied in both diabetics and non-diabetics for the treatment of

systolic heart failure. And so kind of a refresher for our audience, what is the Paglphosin and other

SGLT2 inhibitors?

So we have covered these topics in our previous episodes, number 16 and number 35.

We know that there are about four agents available since 2013, first one being Kanaglophosen,

Nain Makana.

The polyphalosin, which is far as Siga, we're going to talk about that today, Impaglophosin

Jardions and Artuglophosin Stiglaro.

And, you know, the mechanism of this fairly novel drug class, they're called SGLT2 inhibitors,

and they basically inhibit glucose reuptake in the proximal tubule of the kidney.

...